TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

BACKGROUND: Taxane-platinum therapy (TP) has replaced platinum-based therapy (PC or PAC, DNA damaging chemotherapy) in the postoperative treatment of ovarian cancer patients; however, it is not always effective. TP53 protein plays a differential role in response to DNA-damaging agents and taxanes. W...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kupryjanczyk, Jolanta, Kraszewska, Ewa, Ziolkowska-Seta, Izabela, Madry, Radoslaw, Timorek, Agnieszka, Markowska, Janina, Stelmachow, Jerzy, Bidzinski, Mariusz
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2008
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2268700/
https://ncbi.nlm.nih.gov/pubmed/18230133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-8-27
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars